MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease.

B. Adebisi (osogbo, Nigeria)

Meeting: 2023 International Congress

Abstract Number: 1344

Keywords: Alpha-synuclein, Mitochondrial dysfunction, Parkinson’s

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: Alpha synuclein aggregation have been indicted in the process of neuronal cell loss in Parkinson’s disease; however, there have been several hypothesis to explain the processes involved in how alpha synuclein aggregates induce cell damage, thus, the research looked into the pathology of Parkinson’s disease based on the localization of alpha synuclein in the mitochondria and how the neuronal injury is caused.

Background: The aim of the research is to link the dysfunctional state of the mitochondria in neurons to the overexpression of alpha synuclein, protein aggregation and synucleinopathies and also, on the flip side, elucidate the role alpha synuclein aggregates play on the alteration of mitochondrial morphology, reduced respiratory chain complex activities and impairment of mitochondrial functions, which further accelerates aggregation of the protein.

Method: Mitochondrial integrity, respiration and health were examined using several markers of mitochondrial dynamics and stress response and by measuring the rate of oxygen consumption in neuronal cells, expressing oligomeric alpha synuclein.

Results: Alpha synuclein aggregation in presynaptic neurons are said to alter dopamine metabolism and recyclying in the cytoplasm of the neuron, the impaired metabolism has been linked to release of oxidative radicals which find their way to the mitochondria, initiating oxidative stress and damage. Additionally, oligomeric forms of alpha synuclein have been found in the mitochondria which induces a decrease in Sirtuin3, SIRT3, via reduced phosphorylation of cAMP-response Element Binding protein, (CREB), decrease in the phosphorylation of Adenosine Monophosphate activated Protein Kinase, (AMPK) and biogenesis. Increase phosphorylation of dynamin-related protein, (DRP1), which is indicative of impaired mitochondria dynamics and also reduced oxygen consumption, suggesting deficit in mitochondria respiration.

Conclusion: The findings suggest that therapeutic intervention targeted at increasing Mitochondrial SIRT3 might be imperative to attenuate mitochondrial dysfunction induced by alpha synuclein aggregation, towards normalising mitochondrial respiratory chain function, homeostasis, metabolism. Bioenergetics and mitochondrial protection.

To cite this abstract in AMA style:

B. Adebisi. The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease. [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/the-induction-of-mitochondrial-damage-by-alpha-synuclein-in-parkinsons-disease/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/the-induction-of-mitochondrial-damage-by-alpha-synuclein-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley